EP1848997A4 - Composition convenant pour la prevention, le traitement et le diagnostic de la broncho-pneumopathie chronique obstructive (bpco) - Google Patents

Composition convenant pour la prevention, le traitement et le diagnostic de la broncho-pneumopathie chronique obstructive (bpco)

Info

Publication number
EP1848997A4
EP1848997A4 EP06715833A EP06715833A EP1848997A4 EP 1848997 A4 EP1848997 A4 EP 1848997A4 EP 06715833 A EP06715833 A EP 06715833A EP 06715833 A EP06715833 A EP 06715833A EP 1848997 A4 EP1848997 A4 EP 1848997A4
Authority
EP
European Patent Office
Prior art keywords
copd
diagnosis
prevention
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06715833A
Other languages
German (de)
English (en)
Other versions
EP1848997B9 (fr
EP1848997A1 (fr
EP1848997B1 (fr
Inventor
Sook-Yeong Jeon
Dong-Ho Nahm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020060010285A external-priority patent/KR100756972B1/ko
Application filed by Individual filed Critical Individual
Priority to SI200631507T priority Critical patent/SI1848997T1/sl
Publication of EP1848997A1 publication Critical patent/EP1848997A1/fr
Publication of EP1848997A4 publication Critical patent/EP1848997A4/fr
Application granted granted Critical
Publication of EP1848997B1 publication Critical patent/EP1848997B1/fr
Publication of EP1848997B9 publication Critical patent/EP1848997B9/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP06715833A 2005-02-05 2006-02-03 Composition convenant pour la prevention, le traitement et le diagnostic de la broncho-pneumopathie chronique obstructive (bpco) Active EP1848997B9 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI200631507T SI1848997T1 (sl) 2005-02-05 2006-02-03 Sestavek za preprečevanje, zdravljenje in diagnozo kronične obstrukcijske pljučne bolezni (KOPB)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20050010924 2005-02-05
KR1020060010285A KR100756972B1 (ko) 2005-02-05 2006-02-02 만성폐쇄성폐질환의 예방, 치료 및 진단용 조성물 및 방법
PCT/KR2006/000380 WO2006083126A1 (fr) 2005-02-05 2006-02-03 Composition convenant pour la prevention, le traitement et le diagnostic de la broncho-pneumopathie chronique obstructive (bpco)

Publications (4)

Publication Number Publication Date
EP1848997A1 EP1848997A1 (fr) 2007-10-31
EP1848997A4 true EP1848997A4 (fr) 2008-10-01
EP1848997B1 EP1848997B1 (fr) 2012-11-21
EP1848997B9 EP1848997B9 (fr) 2013-03-27

Family

ID=36777470

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06715833A Active EP1848997B9 (fr) 2005-02-05 2006-02-03 Composition convenant pour la prevention, le traitement et le diagnostic de la broncho-pneumopathie chronique obstructive (bpco)

Country Status (2)

Country Link
EP (1) EP1848997B9 (fr)
WO (1) WO2006083126A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2224244A1 (fr) * 2009-02-26 2010-09-01 Universität des Saarlandes Procédé de diagnostic in vitro ou analyse pour le diagnostic de bronchopneumopathie chronique obstructive
US10035821B2 (en) 2016-10-21 2018-07-31 Gunnar C. Hansson Calcium binding compounds based on gamma-carboxy glutamate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023002A2 (fr) * 2001-09-07 2003-03-20 Curagen Corporation Nouvelles proteines humaines, polynucleotides codant ces proteines et procedes d'utilisation associes
WO2003098211A1 (fr) * 2002-05-15 2003-11-27 Dong-Ho Nahm Detection d'anticorps diriges contre la proteine cytokeratine 18 chez des patients souffrant d'asthme et de rhinite chronique, et applications de ladite detection sous la forme d'un kit servant a diagnostiquer l'asthme et une rhinite chronique et comprenant la proteine humaine cytokeratine 18
WO2006073254A1 (fr) * 2005-01-03 2006-07-13 Sook-Yeong Jeon Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023002A2 (fr) * 2001-09-07 2003-03-20 Curagen Corporation Nouvelles proteines humaines, polynucleotides codant ces proteines et procedes d'utilisation associes
WO2003098211A1 (fr) * 2002-05-15 2003-11-27 Dong-Ho Nahm Detection d'anticorps diriges contre la proteine cytokeratine 18 chez des patients souffrant d'asthme et de rhinite chronique, et applications de ladite detection sous la forme d'un kit servant a diagnostiquer l'asthme et une rhinite chronique et comprenant la proteine humaine cytokeratine 18
WO2006073254A1 (fr) * 2005-01-03 2006-07-13 Sook-Yeong Jeon Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEFFERY PETER K: "Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease.", 2004, PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY 2004, VOL. 1, NR. 3, PAGE(S) 176 - 183, ISSN: 1546-3222, XP002491922 *
RYU J H ET AL: "Obstructive lung diseases: COPD, asthma, and many imitators.", MAYO CLINIC PROCEEDINGS. MAYO CLINIC NOV 2001, vol. 76, no. 11, November 2001 (2001-11-01), pages 1144 - 1153, XP002491921, ISSN: 0025-6196 *
See also references of WO2006083126A1 *

Also Published As

Publication number Publication date
WO2006083126A1 (fr) 2006-08-10
EP1848997B9 (fr) 2013-03-27
EP1848997A1 (fr) 2007-10-31
EP1848997B1 (fr) 2012-11-21

Similar Documents

Publication Publication Date Title
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
EP2007385A4 (fr) Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
EP1865967A4 (fr) Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
CA2645871A1 (fr) Compositions pharmaceutiques et methodes destinees a traiterou prevenir une maladie associee a l'oxalate
EP1853295A4 (fr) Procedes et compositions pour le traitement de troubles gastro-intestinaux
EP1940441A4 (fr) Compositions et methodes de traitement de troubles gastro-intestinaux
ZA200801706B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1978986A4 (fr) Procédés et compositions basés sur des micro-arn et s'appliquant au diagnostic, au pronostic et au traitement du cancer du poumon
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
ZA200800452B (en) Methods and compositions for the prevention and treatment of kidney disease
EP1773374A4 (fr) Agent comprenant le fgf2 comme ingredient actif pour le traitement ou la prevention de l'asthme et de la bronchopneumopathie chronique obstructive
ZA200708819B (en) Methods and compositions for the prevention and treatment of kidney disease
EP2038413A4 (fr) Appareil, compositions et procedes d'evaluation de la progression d'une bronchopneumopathie chronique obstructive parmi des conditions de declin rapide et lent
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
HK1141708A1 (en) Agent for treatment of pulmonary disease
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
IL199022A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
EP1954800A4 (fr) Composition et utilisation d'un phyto-percolate pour le traitement d'une maladie
EP1928247A4 (fr) Composition et utilisation de phyto-percolate pour le traitement d'une maladie
EP1843781A4 (fr) Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes
SI2366393T1 (sl) Roflumilast za zdravljenje pljučne hipertenzije
EP2151451A4 (fr) Composition pour empêcher ou traiter une maladie pulmonaire
WO2006086609A3 (fr) Inhibiteurs de la tryptase
SI1848997T1 (sl) Sestavek za preprečevanje, zdravljenje in diagnozo kronične obstrukcijske pljučne bolezni (KOPB)
EP1875915A4 (fr) Agent therapeutique permettant de traiter une maladie respiratoire obstructive chronique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070814

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080902

17Q First examination report despatched

Effective date: 20081216

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 585329

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006033189

Country of ref document: DE

Effective date: 20130117

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 585329

Country of ref document: AT

Kind code of ref document: T

Effective date: 20121121

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2403905

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130522

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130222

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130321

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130221

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

26N No opposition filed

Effective date: 20130822

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006033189

Country of ref document: DE

Effective date: 20130822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060203

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130203

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121121

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602006033189

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230228

Year of fee payment: 18

Ref country code: ES

Payment date: 20230310

Year of fee payment: 18

Ref country code: DK

Payment date: 20230222

Year of fee payment: 18

Ref country code: CH

Payment date: 20230307

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20230215

Year of fee payment: 18

Ref country code: IT

Payment date: 20230222

Year of fee payment: 18

Ref country code: GB

Payment date: 20230227

Year of fee payment: 18

Ref country code: DE

Payment date: 20230222

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230222

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20240131

Year of fee payment: 19